HR positive

P2, N=90, Recruiting, Delcath Systems Inc. | Not yet recruiting --> Recruiting

A DE approach to abemaciclib was associated with significantly fewer treatment interruptions and dose reductions while maintaining similar discontinuation rates compared with SD. These findings suggest that DE may improve early tolerability, support treatment adherence, and optimize clinical outcomes in high-risk HR+, HER2-, EBC patients.

N+T in patients with HER2-mutant metastatic TNBC appeared to prolong responses versus neratinib alone, representing a novel approach for biomarker-defined metastatic TNBC patients. Based on these and previously published data, neratinib-based combinations are endorsed by NCCN guidelines for patients with hormone receptor-positive or -negative metastatic breast cancer with activating HER2 mutations.

P1, N=78, Recruiting, Tasly Pharmaceutical Group Co., Ltd

P3, N=400, Recruiting, Pfizer

P2, N=191, Active, not recruiting, University of Rochester | Trial completion date: Dec 2025 --> Dec 2026

P3, N=984, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting | N=540 --> 984 | Trial completion date: Jun 2027 --> Apr 2028

P1, N=13, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed

Patients with endocrine-sensitive disease at the time of BrM diagnosis had a longer brain-specific progression-free survival (7 mo versus 5 months, P = .004) and overall survival (24 months versus 5 mo, P  = .002) compared with those with endocrine resistance. Most patients with HR+/HER2- BrM have endocrine-resistant disease, with an unexpectedly high likelihood of developing LMD.

Prompt recognition, intensive management, and drug discontinuation are critical. This is one of the first case reports to describe sustained euglycemia following severe and refractory hyperglycemia due to capivasertib therapy.

P=N/A, N=60, Recruiting, Hubei Cancer Hospital | Not yet recruiting --> Recruiting

By contrast, sacituzumab govitecan is a TROP-2-targeted ADC conjugated through a hydrolysable CL2A linker to SN-38, the active metabolite of irinotecan. Clinically, trastuzumab deruxtecan has shown substantial efficacy in both HER2-positive and HER2-low breast cancer, whereas sacituzumab govitecan has demonstrated efficacy across triple-negative and hormone receptor-positive/HER2-negative breast cancers. Collectively, these agents highlight how variations in target antigen, linker chemistry, and payload potency impact ADC activity, therapeutic index, and potential strategies for sequential treatment in advanced breast cancer.